OnBioVChttp://onbiovc.comYour Source for BioScience Venture Capital Dataenhttp://wordpress.org/?v=2.6.5onbiovc/NCeLhttp://feedburner.google.comVytronUS, Inc.: Series B $11Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/1eI3amJlMe0/I - Series BQ - 2Q09R - WESTX - Device (Cardiology)XX - CAarubensteinSun, 05 Jul 2009 19:39:02 PDThttp://onbiovc.com/?p=1231VytronUS (Sunnyvale, CA) a stealth, assumed early-stage cardiac medical device company focused on cardiology, closed an $11M Series B financing. Participants include Delphi Ventures and New Enterprise Associates.

]]>VytronUS (Sunnyvale, CA) a stealth, assumed early-stage cardiac medical device company focused on cardiology, closed an $11M Series B financing. Participants include Delphi Ventures and New Enterprise Associates.http://onbiovc.com/vytronus-inc-series-b-11m/feed/http://onbiovc.com/vytronus-inc-series-b-11m/Gyros, AB: Series C* $10.4Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/ZI-NsPp0rRI/I - Series CQ - 2Q09R - INTERNATIONALX - Device (Protein Assay)arubensteinSun, 05 Jul 2009 19:37:28 PDThttp://onbiovc.com/?p=1229Gyros (Sweden) a commercial-stage provider of platform-based tools for therapeutic protein assay optimization, closed a $10.4M Series C* financing. Participants include SLS Invest and Industrifonden.

*Investment round undisclosed

]]>Gyros (Sweden) a commercial-stage provider of platform-based tools for therapeutic protein assay optimization, closed a $10.4M Series C* financing. Participants include SLS Invest and Industrifonden. *Investment round undisclosedhttp://onbiovc.com/gyros-ab-series-c-104m/feed/http://onbiovc.com/gyros-ab-series-c-104m/Savara Pharmaceuticals, Inc.: Series A $1.0Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/Dcec6mo_Z-Q/I - Series AQ - 2Q09R - SOUTH WESTX - Device (Delivery)XX - TXarubensteinSun, 05 Jul 2009 19:28:59 PDThttp://onbiovc.com/?p=1227Savara Pharmaceuticals (Austin, TX) a preclinical-stage developer of dry powder and nebulized-based therapeutic inhalation drug delivery platform, closed a $1.0M Series A financing. Participants were not identified.

]]>Savara Pharmaceuticals (Austin, TX) a preclinical-stage developer of dry powder and nebulized-based therapeutic inhalation drug delivery platform, closed a $1.0M Series A financing. Participants were not identified.http://onbiovc.com/savara-pharmaceuticals-inc-series-a-10m/feed/http://onbiovc.com/savara-pharmaceuticals-inc-series-a-10m/Embrella Cardiovascular, Inc.: Series B $5.1Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/UxWeByWXHMQ/I - Series BQ - 2Q09R - NORTH EASTX - Device (Cardiology)XX - PAarubensteinSun, 05 Jul 2009 19:27:16 PDThttp://onbiovc.com/?p=1225Embrella Cardiovascular (Malvern, PA) an early-stage medical device company focused on cerebral embolic protection during cardiovascular procedures, closed a $5.1M Series B financing. Participants include BioStarVentures, Edwards Lifesciences and MedFocus Fund.

]]>Embrella Cardiovascular (Malvern, PA) an early-stage medical device company focused on cerebral embolic protection during cardiovascular procedures, closed a $5.1M Series B financing. Participants include BioStarVentures, Edwards Lifesciences and MedFocus Fund.http://onbiovc.com/embrella-cardiovascular-inc-series-b-51m/feed/http://onbiovc.com/embrella-cardiovascular-inc-series-b-51m/Capella, Inc.: Series C $17.3Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/kS0XmcU4iJM/I - Series CQ - 2Q09R - INTERNATIONALX - Device (Cardiology)X - Device (Stent)X - Device (Vascular)arubensteinSun, 28 Jun 2009 19:56:50 PDThttp://onbiovc.com/?p=1223Capella (Ireland) a development-stage medical device company focused on stents for bifurcation vascular disease complex coronary artery disease, cloased a $17.3M Series C financing. Participants include Fountain Healthcare Partners, Mitsui & Co., Enterprise Ireland, Polytechnos Partners and ACT Venture Capital.

]]>Capella (Ireland) a development-stage medical device company focused on stents for bifurcation vascular disease complex coronary artery disease, cloased a $17.3M Series C financing. Participants include Fountain Healthcare Partners, Mitsui & Co., Enterprise Ireland, Polytechnos Partners and ACT Venture Capital.http://onbiovc.com/capella-inc-series-c-173m/feed/http://onbiovc.com/capella-inc-series-c-173m/Solazyme, Inc.: Series C $57Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/3OxnNMsHyWA/I - Series CQ - 2Q09R - WESTX - BiofuelXX - CAarubensteinSun, 28 Jun 2009 19:54:28 PDThttp://onbiovc.com/?p=1221Solazyme (San Francisco, CA) a development-stage biofuels company focused on the bioproduction of microalgae molecules for the energy, chemical, and nutraceutical industries, closed a $57M Series C financing. Participants include Braemar Energy Ventures, Lightspeed Venture Partners, VantagePoint Venture Partners, Roda Group and Harris & Harris Group.

]]>Solazyme (San Francisco, CA) a development-stage biofuels company focused on the bioproduction of microalgae molecules for the energy, chemical, and nutraceutical industries, closed a $57M Series C financing. Participants include Braemar Energy Ventures, Lightspeed Venture Partners, VantagePoint Venture Partners, Roda Group and Harris & Harris Group.http://onbiovc.com/solazyme-inc-series-c-57m/feed/http://onbiovc.com/solazyme-inc-series-c-57m/NanoString Technologies, Inc.: Series C $30Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/7Ip0rG4-ji0/I - Series CQ - 2Q09R - NORTH WESTX - BioinformaticsXX - WAarubensteinSun, 28 Jun 2009 19:51:57 PDThttp://onbiovc.com/?p=1219NanoString Technologies (Seattle, WA) a commercial-stage developer of instrumentation and assays for multiplexed detection and quantification of gene expression, closed a $30M Series C financing. Participants include Clarus Ventures, OVP Venture Partners and Draper Fisher Jurvetson.

]]>NanoString Technologies (Seattle, WA) a commercial-stage developer of instrumentation and assays for multiplexed detection and quantification of gene expression, closed a $30M Series C financing. Participants include Clarus Ventures, OVP Venture Partners and Draper Fisher Jurvetson.http://onbiovc.com/nanostring-technologies-inc-series-c-30m/feed/http://onbiovc.com/nanostring-technologies-inc-series-c-30m/Inspire Medical Systems, Inc.: Series B $17Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/KmHHHw5ryqM/I - Series BQ - 2Q09R - MID WESTXX - MNarubensteinSun, 28 Jun 2009 19:49:37 PDThttp://onbiovc.com/?p=1217Inspire Medical Systems (Minneapolis, MN) an early-stage medical device company developing an implantable therapeutic device for the treatment of obstructive sleep apnea, closed a $17M Series B financing. Participants include Kleiner Perkins Caufield & Byers, Medtronic and U.S. Venture Partners.

]]>Inspire Medical Systems (Minneapolis, MN) an early-stage medical device company developing an implantable therapeutic device for the treatment of obstructive sleep apnea, closed a $17M Series B financing. Participants include Kleiner Perkins Caufield & Byers, Medtronic and U.S. Venture Partners.http://onbiovc.com/inspire-medical-systems-inc-series-b-17m/feed/http://onbiovc.com/inspire-medical-systems-inc-series-b-17m/Spiracur, Inc.: Series B $20.3Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/tqa7kanQ_EI/I - Series BQ - 2Q09R - WESTX - Device (Wound Healing)X - Wound HealingXX - CAarubensteinSun, 28 Jun 2009 19:47:24 PDThttp://onbiovc.com/?p=1215Spiracur (Redwood City, CA) and early-stage medical device company focused on wound healing, closed a $20.3M Series B financing. Participants include Kleiner Perkins Caufield & Byers, New Leaf Venture Partners and De Novo Ventures.

]]>Spiracur (Redwood City, CA) and early-stage medical device company focused on wound healing, closed a $20.3M Series B financing. Participants include Kleiner Perkins Caufield & Byers, New Leaf Venture Partners and De Novo Ventures.http://onbiovc.com/spiracur-inc-series-b-203m/feed/http://onbiovc.com/spiracur-inc-series-b-203m/Inimex Pharmaceuticals, Inc.: Series B $22Mhttp://feedproxy.google.com/~r/onbiovc/NCeL/~3/6_uM0J0Or_8/I - Series BQ - 2Q09R - INTERNATIONALX - ImmunologyX - InflammationarubensteinThu, 25 Jun 2009 22:03:03 PDThttp://onbiovc.com/?p=1213Inimex Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company focused on infectious diseases and inflammatory disorders, closed a $22M Series B financing. Participants include Morningside, Roche Venture Fund, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Venture Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund, and Working Opportunity Fund.

]]>Inimex Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company focused on infectious diseases and inflammatory disorders, closed a $22M Series B financing. Participants include Morningside, Roche Venture Fund, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Venture Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund, and Working Opportunity Fund.http://onbiovc.com/inimex-pharmaceuticals-inc-series-b-22m-2/feed/http://onbiovc.com/inimex-pharmaceuticals-inc-series-b-22m-2/